Baxalta to Present at Credit Suisse Healthcare Conference

BANNOCKBURN, Ill.--(BUSINESS WIRE)-- Baxalta Incorporated (NYSE: BXLT) announced today that it will present at the Credit Suisse Healthcare Conference on Wednesday, Nov. 11, 2015, at 12:30 p.m. Central Time.

The live webcast of Baxalta’s presentation along with the accompanying slides will be accessible from the Baxalta corporate website at investor.baxalta.com.

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151102005032/en/

Baxalta Media Relations
Geoffrey Mogilner, +1-224-940-8619
[email protected]
or
Baxalta Investor Relations
Mary Kay Ladone, +1-224-948-3371
[email protected]
or
Lorna Williams, +1-224-948-3511
[email protected]

Source: Baxalta Incorporated

You May Also Be Interested In

• Pigeon Pea Market Size to Reach $9.50 Billion by 2031, Driven by Plant-Based Proteins Demand & East African Exports – Mordor Intelligence
• Nelnet to Announce Third Quarter Results
• Freight Forwarding Market to Hit USD 776.04 Billion by 2031, Says Mordor Intelligence